GSK's Bepirovirsen Accepted for Expedited Regulatory Review in Japan for Chronic Hepatitis B

summarizeSummary

Japan's MHLW has accepted GSK's new drug application for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B, for expedited review. This marks the first global regulatory filing for the drug.

check_boxKey Events

• Regulatory Review Accepted in Japan

  Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted GSK's New Drug Application (NDA) for bepirovirsen.

• Expedited Review Status

  Bepirovirsen was granted SENKU designation in Japan in August 2024, enabling an expedited regulatory review process.

• Potential First-in-Class Treatment

  The investigational antisense oligonucleotide (ASO) is a potential first-in-class treatment for chronic hepatitis B, a condition affecting nearly one million people in Japan.

• Supported by Positive Phase III Data

  The regulatory submission is backed by statistically significant and clinically meaningful functional cure rates demonstrated in pivotal Phase III B-Well trials.

auto_awesomeAnalysis

Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted GSK's New Drug Application for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B. This marks a significant advancement in the drug's development, following positive Phase III B-Well trials. The SENKU designation, granted in August 2024, ensures an expedited review process, potentially accelerating market access in Japan, a country where nearly one million people live with chronic hepatitis B. This is the first global regulatory filing for bepirovirsen, signaling progress towards commercialization for a drug targeting a major public health challenge.